2023 A new French revolution: Organ preservation for rectal cancer
Cancer Radiother. 2024 Mar 19:S1278-3218(24)00025-8. doi: 10.1016/j.canrad.2024.02.001. Online ahead of print.NO ABSTRACTPMID:38508953 | DOI:10.1016/j.canrad.2024.02.001 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - March 20, 2024 Category: Cancer & Oncology Authors: J-P G érard Source Type: research
2023 A new French revolution: Organ preservation for rectal cancer
Cancer Radiother. 2024 Mar 19:S1278-3218(24)00025-8. doi: 10.1016/j.canrad.2024.02.001. Online ahead of print.NO ABSTRACTPMID:38508953 | DOI:10.1016/j.canrad.2024.02.001 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - March 20, 2024 Category: Cancer & Oncology Authors: J-P G érard Source Type: research
Frameless trigeminal neuralgia radiosurgery with a dedicated linear accelerator: From equipment commissioning to initial clinical results
CONCLUSION: The treatment of trigeminal neuralgia on a dedicated linear accelerator is a highly technical treatment whose accuracy and safety are paramount. The physical measurements allowed the commissioning of the technique with a 6mm cone. Our first clinical results are in accordance with the literature.PMID:38490925 | DOI:10.1016/j.canrad.2023.07.017 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - March 15, 2024 Category: Cancer & Oncology Authors: É Queyrel M Lanaret T Khalil M Al Gahatany R Chaix J-J Lemaire X Moisset V Chassin L Brun V Dedieu J Biau Source Type: research
Frameless trigeminal neuralgia radiosurgery with a dedicated linear accelerator: From equipment commissioning to initial clinical results
CONCLUSION: The treatment of trigeminal neuralgia on a dedicated linear accelerator is a highly technical treatment whose accuracy and safety are paramount. The physical measurements allowed the commissioning of the technique with a 6mm cone. Our first clinical results are in accordance with the literature.PMID:38490925 | DOI:10.1016/j.canrad.2023.07.017 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - March 15, 2024 Category: Cancer & Oncology Authors: É Queyrel M Lanaret T Khalil M Al Gahatany R Chaix J-J Lemaire X Moisset V Chassin L Brun V Dedieu J Biau Source Type: research
Frameless trigeminal neuralgia radiosurgery with a dedicated linear accelerator: From equipment commissioning to initial clinical results
CONCLUSION: The treatment of trigeminal neuralgia on a dedicated linear accelerator is a highly technical treatment whose accuracy and safety are paramount. The physical measurements allowed the commissioning of the technique with a 6mm cone. Our first clinical results are in accordance with the literature.PMID:38490925 | DOI:10.1016/j.canrad.2023.07.017 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - March 15, 2024 Category: Cancer & Oncology Authors: É Queyrel M Lanaret T Khalil M Al Gahatany R Chaix J-J Lemaire X Moisset V Chassin L Brun V Dedieu J Biau Source Type: research
Frameless trigeminal neuralgia radiosurgery with a dedicated linear accelerator: From equipment commissioning to initial clinical results
CONCLUSION: The treatment of trigeminal neuralgia on a dedicated linear accelerator is a highly technical treatment whose accuracy and safety are paramount. The physical measurements allowed the commissioning of the technique with a 6mm cone. Our first clinical results are in accordance with the literature.PMID:38490925 | DOI:10.1016/j.canrad.2023.07.017 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - March 15, 2024 Category: Cancer & Oncology Authors: É Queyrel M Lanaret T Khalil M Al Gahatany R Chaix J-J Lemaire X Moisset V Chassin L Brun V Dedieu J Biau Source Type: research
Frameless trigeminal neuralgia radiosurgery with a dedicated linear accelerator: From equipment commissioning to initial clinical results
CONCLUSION: The treatment of trigeminal neuralgia on a dedicated linear accelerator is a highly technical treatment whose accuracy and safety are paramount. The physical measurements allowed the commissioning of the technique with a 6mm cone. Our first clinical results are in accordance with the literature.PMID:38490925 | DOI:10.1016/j.canrad.2023.07.017 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - March 15, 2024 Category: Cancer & Oncology Authors: É Queyrel M Lanaret T Khalil M Al Gahatany R Chaix J-J Lemaire X Moisset V Chassin L Brun V Dedieu J Biau Source Type: research
Comments on "An umbrella review exploring the effect of radiotherapy for head and neck cancer patients on the frequency of jaws osteoradionecrosis"
Cancer Radiother. 2024 Mar 13:S1278-3218(24)00027-1. doi: 10.1016/j.canrad.2023.07.016. Online ahead of print.NO ABSTRACTPMID:38485574 | DOI:10.1016/j.canrad.2023.07.016 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - March 14, 2024 Category: Cancer & Oncology Authors: B Yilmaz U Selek Source Type: research
Practice-changing clinical trials in radiation oncology for gastrointestinal malignancies in 2021-2023
Cancer Radiother. 2023 Dec;27(8):768-777. doi: 10.1016/j.canrad.2023.08.001. Epub 2023 Oct 26.ABSTRACTGastrointestinal cancers are one of the most frequent cancers and a leading cause of cancer deaths worldwide. We provide an overview of the most important practice-changing trials that were either published or presented at the international scientific meetings in 2021-2023. Highlights included reports on three phase III trials (CONCORDE/PRODIGE 26, ARTDECO, and a study by Xu et al.) that evaluated dose escalation in the definitive setting for locally advanced oesophageal cancers, as well as two phase III trials that evalua...
Source: Cancer Radiotherapie - February 28, 2024 Category: Cancer & Oncology Authors: J Boustani F Huguet V Vendrely Source Type: research
Practice-changing clinical trials in radiation oncology for gastrointestinal malignancies in 2021-2023
Cancer Radiother. 2023 Dec;27(8):768-777. doi: 10.1016/j.canrad.2023.08.001. Epub 2023 Oct 26.ABSTRACTGastrointestinal cancers are one of the most frequent cancers and a leading cause of cancer deaths worldwide. We provide an overview of the most important practice-changing trials that were either published or presented at the international scientific meetings in 2021-2023. Highlights included reports on three phase III trials (CONCORDE/PRODIGE 26, ARTDECO, and a study by Xu et al.) that evaluated dose escalation in the definitive setting for locally advanced oesophageal cancers, as well as two phase III trials that evalua...
Source: Cancer Radiotherapie - February 28, 2024 Category: Cancer & Oncology Authors: J Boustani F Huguet V Vendrely Source Type: research
Practice-changing clinical trials in radiation oncology for gastrointestinal malignancies in 2021-2023
Cancer Radiother. 2023 Dec;27(8):768-777. doi: 10.1016/j.canrad.2023.08.001. Epub 2023 Oct 26.ABSTRACTGastrointestinal cancers are one of the most frequent cancers and a leading cause of cancer deaths worldwide. We provide an overview of the most important practice-changing trials that were either published or presented at the international scientific meetings in 2021-2023. Highlights included reports on three phase III trials (CONCORDE/PRODIGE 26, ARTDECO, and a study by Xu et al.) that evaluated dose escalation in the definitive setting for locally advanced oesophageal cancers, as well as two phase III trials that evalua...
Source: Cancer Radiotherapie - February 28, 2024 Category: Cancer & Oncology Authors: J Boustani F Huguet V Vendrely Source Type: research
Practice-changing clinical trials in radiation oncology for gastrointestinal malignancies in 2021-2023
Cancer Radiother. 2023 Dec;27(8):768-777. doi: 10.1016/j.canrad.2023.08.001. Epub 2023 Oct 26.ABSTRACTGastrointestinal cancers are one of the most frequent cancers and a leading cause of cancer deaths worldwide. We provide an overview of the most important practice-changing trials that were either published or presented at the international scientific meetings in 2021-2023. Highlights included reports on three phase III trials (CONCORDE/PRODIGE 26, ARTDECO, and a study by Xu et al.) that evaluated dose escalation in the definitive setting for locally advanced oesophageal cancers, as well as two phase III trials that evalua...
Source: Cancer Radiotherapie - February 28, 2024 Category: Cancer & Oncology Authors: J Boustani F Huguet V Vendrely Source Type: research
Practice-changing clinical trials in radiation oncology for gastrointestinal malignancies in 2021-2023
Cancer Radiother. 2023 Dec;27(8):768-777. doi: 10.1016/j.canrad.2023.08.001. Epub 2023 Oct 26.ABSTRACTGastrointestinal cancers are one of the most frequent cancers and a leading cause of cancer deaths worldwide. We provide an overview of the most important practice-changing trials that were either published or presented at the international scientific meetings in 2021-2023. Highlights included reports on three phase III trials (CONCORDE/PRODIGE 26, ARTDECO, and a study by Xu et al.) that evaluated dose escalation in the definitive setting for locally advanced oesophageal cancers, as well as two phase III trials that evalua...
Source: Cancer Radiotherapie - February 28, 2024 Category: Cancer & Oncology Authors: J Boustani F Huguet V Vendrely Source Type: research
Practice-changing clinical trials in radiation oncology for gastrointestinal malignancies in 2021-2023
Cancer Radiother. 2023 Dec;27(8):768-777. doi: 10.1016/j.canrad.2023.08.001. Epub 2023 Oct 26.ABSTRACTGastrointestinal cancers are one of the most frequent cancers and a leading cause of cancer deaths worldwide. We provide an overview of the most important practice-changing trials that were either published or presented at the international scientific meetings in 2021-2023. Highlights included reports on three phase III trials (CONCORDE/PRODIGE 26, ARTDECO, and a study by Xu et al.) that evaluated dose escalation in the definitive setting for locally advanced oesophageal cancers, as well as two phase III trials that evalua...
Source: Cancer Radiotherapie - February 28, 2024 Category: Cancer & Oncology Authors: J Boustani F Huguet V Vendrely Source Type: research
Practice-changing clinical trials in radiation oncology for gastrointestinal malignancies in 2021-2023
Cancer Radiother. 2023 Dec;27(8):768-777. doi: 10.1016/j.canrad.2023.08.001. Epub 2023 Oct 26.ABSTRACTGastrointestinal cancers are one of the most frequent cancers and a leading cause of cancer deaths worldwide. We provide an overview of the most important practice-changing trials that were either published or presented at the international scientific meetings in 2021-2023. Highlights included reports on three phase III trials (CONCORDE/PRODIGE 26, ARTDECO, and a study by Xu et al.) that evaluated dose escalation in the definitive setting for locally advanced oesophageal cancers, as well as two phase III trials that evalua...
Source: Cancer Radiotherapie - February 28, 2024 Category: Cancer & Oncology Authors: J Boustani F Huguet V Vendrely Source Type: research
